{"doi":"10.1002/acr2.70112","title":"Associations Between Pre‐Existing Autoimmunity and Chimeric Antigen Receptor T Cell Therapy Toxicity for Cancer Treatment","abstract":"OBJECTIVE: Chimeric antigen receptor (CAR) T cell therapy is being investigated to treat individuals with autoimmune diseases. Data regarding the safety of CAR T cell therapy in this population are limited. We aimed to assess whether pre-existing autoimmune disease was associated with an increase in major toxicity or hospital length of stay (LOS) among patients receiving CAR T cell therapy for the treatment of hematologic cancer. METHODS: This retrospective cohort study used data from the National Inpatient Sample (2021-2022) to investigate in-hospital outcomes in adult patients receiving CAR T cell therapy. Comparisons were drawn between patients with and without pre-existing autoimmune disease. Multivariable regression models with adjustment for age, sex, race, cancer type, and comorbidities assessed associations with hospital LOS, major toxicity, and inpatient mortality. RESULTS: Among 1,321 patients receiving CAR T cell therapy, 62 (4.7%) had diagnosed autoimmune disease. Patients with pre-existing autoimmunity had a significantly shorter hospital stay compared with patients without, with a mean reduction of 2.1 days (95% confidence interval [CI] 0.5-3.6). Major toxicity was less frequent in patients with pre-existing autoimmunity than patients without (67.7% vs 78.6%, respectively; adjusted odds ratio 0.55; 95% CI 0.31-0.99). Inpatient mortality did not differ significantly between groups. CONCLUSION: Patients with pre-existing autoimmune disease had shorter hospital stays and lower risk of major toxicity following CAR T cell therapy for cancer treatment, offering reassurance as to its safety in this population while providing additional data for research studies of CAR T cell therapy to treat autoimmune diseases.","journal":"ACR Open Rheumatology","year":2025,"id":536926,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9607,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1422246,"name":"Chen Wang","orcid":"0000-0001-7071-6213","position":1,"is_corresponding":false},{"id":1055337,"name":"David Gritsch","orcid":"0000-0003-0138-2357","position":2,"is_corresponding":false},{"id":1422247,"name":"Ilana M. Usiskin","orcid":"0000-0001-5527-2597","position":3,"is_corresponding":false},{"id":707796,"name":"Zandra E. Walton","orcid":"0000-0002-0465-0153","position":4,"is_corresponding":false},{"id":703965,"name":"Minna J. Kohler","orcid":"0000-0001-6450-7546","position":5,"is_corresponding":false},{"id":236763,"name":"Hyon K. Choi","orcid":"0000-0002-2862-0442","position":6,"is_corresponding":false},{"id":236764,"name":"Jeffrey A. Sparks","orcid":"0000-0002-5556-4618","position":7,"is_corresponding":false},{"id":1265954,"name":"Gregory J. Challener","orcid":"0000-0002-2844-4661","position":0,"is_corresponding":true}],"reference_count":26,"raw_metadata":null,"created_at":"2026-07-19T02:52:09.056872Z","pmid":"41110994","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}